KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Treasury Shares (2018 - 2025)

Esperion Therapeutics' Treasury Shares history spans 6 years, with the latest figure at $55.0 million for Q4 2025.

  • For Q4 2025, Treasury Shares changed 0.0% year-over-year to $55.0 million; the TTM value through Dec 2025 reached $55.0 million, changed 0.0%, while the annual FY2025 figure was $55.0 million, 0.0% changed from the prior year.
  • Treasury Shares reached $2.0 million in Q4 2025 per ESPR's latest filing, roughly flat from $2.0 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $9.1 million in Q1 2025 to a low of $2.0 million in Q1 2021.
  • Average Treasury Shares over 5 years is $3.0 million, with a median of $2.0 million recorded in 2021.
  • The largest YoY upside for Treasury Shares was 0.0% in 2021 against a maximum downside of 0.0% in 2021.
  • A 5-year view of Treasury Shares shows it stood at $55.0 million in 2021, then changed by 0.0% to $55.0 million in 2022, then changed by 0.0% to $55.0 million in 2023, then changed by 0.0% to $55.0 million in 2024, then changed by 0.0% to $55.0 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Treasury Shares are $55.0 million (Q4 2025), $55.0 million (Q3 2025), and $55.0 million (Q2 2025).